8/3/2020  9:59:54 PM Chg. +0.16 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
3.16USD +5.34% 100,917
Turnover: 311,950.33
-Bid Size: - -Ask Size: - 368.04 mill.USD 0.00% -

Business description

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets five hematology/oncology drugs, and expects an FDA decision on another hematology drug later this year. Additionally, Spectrum's pipeline includes three drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.
 

Management board & Supervisory board

CEO
Joseph Turgeon
Management board
Kurt Gustafson, Francois Lebel, Keith M. McGahan, Thomas J. Riga
Supervisory board
William L. Ashton, Elizabeth A. Czerepak, Joseph W. Turgeon, Raymond W. Cohen
 

Company data

Name: Spectrum Pharmaceuticals Inc.
Address: 11500 S. Eastern Avenue, Suite 240,Henderson, NV 89052, USA
Phone: +1-702-935-6300
Fax: +1-702-260-7405
E-mail: -
Internet: https://www.sppirx.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 60.17%
IPO date: -

Investor relations

Name: Shiv Kapoor
IR phone: -
IR Fax: -
IR e-mail: IR@sppirx.com

Main Shareholders